arrow
Y

Yingjun Yan

Vanderbilt University
H指数:17
被引数:1,400

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

编辑关注声明:同时靶向IGF-1R和ALK在ALK融合阳性肺癌中的合理性

2025-11-200
OAAI
Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

肺癌中EGFR外显子19缺失突变的等位基因特异性激活,酶动力学和抑制剂敏感性

2022-07-2214
OAAI
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
2021-03-0240
OAAI
Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
2021-03-0111
OAAI
Circulating tumor DNA as a potential biomarker of radiographic tumor burden in small cell lung cancer
2020-08-152
PRE
Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

基于血液监测的SCLC患者循环肿瘤DNA监测可检测疾病复发并预测局限期患者的死亡

2020-06-0114
OAAI
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

对突变选择性EGFR抑制剂奥希替尼的靶向耐药可以等位基因特异性方式发展,依赖于原始EGFR激活突变

2019-06-0379
OAAI
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer
2016-06-02111
OAAI
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
2014-08-31260
OAAI